POZITÍVNE STANOVISKO VÝBORU PRE LIEKY NA HUMÁNNE POUŽITIE PODPORUJE ŠIRŠIE POUŽÍVANIE LIEKU REPATHA® OD SPOLOČNOSTI AMGEN PRED PRVÝM INFARKTOM ALEBO MOZGOVOU PRÍHODOU

RegulatoryapprovedRepathaPositive

AI Analysis

Summary

Amgen's Repatha received a positive CHMP opinion supporting expanded use for primary prevention of myocardial infarction and stroke. The approval is based on Phase 3 clinical trial data demonstrating significant reduction in cardiovascular risk.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Positive Committee for Medicinal Products for Human Use (CHMP) opinion supporting broader use of Repatha for primary prevention of myocardial infarction and stroke

Importance:7/10

Sentiment:

0.85

PCSK9 inhibitorcardiovascular diseaseprimary preventionregulatory approvalEuropean approval

Related Companies

$AMGN

Read the original article

Published by PR Newswire Biotech on July 30, 2026 1:25 PM

Read Original